NCT03061474View on ClinicalTrials.gov

Nicotinamide as an Early Alzheimer's Disease Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

July 12, 2017

Primary Completion Date

August 30, 2022

Study Completion Date

August 30, 2022

Conditions
Alzheimer's DiseaseMild Cognitive Impairment
Interventions
DRUG

Nicotinamide

Niacinamide (nicotinamide; 99%) is produced in a 750 mg sustained release tablet.

DRUG

Placebo Comparator

Oral Tablet

Trial Locations (2)

90095

University of California, Los Angeles, Los Angeles

92697

University of California, Irvine, Irvine

All Listed Sponsors
lead

University of California, Irvine

OTHER

NCT03061474 - Nicotinamide as an Early Alzheimer's Disease Treatment | Biotech Hunter | Biotech Hunter